The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Strides is the first Indian company to get approval for the product.
Both manufacturing facilities are based out of Benguluru, India
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Subscribe To Our Newsletter & Stay Updated
